Scholars Central

Short communicationPublished 28 Jul 2022

Sars-cov-2 (covid-19) variants are effectively prevented by current covid-19 vaccines

Authors: Attapon Cheepsattayakorn

Journal of Immunology and Microbiology

Volume 6 · Issue 4 · Pages 1

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The WHO recommendations on COVID-19 vaccines in the context of SARS-CoV-2 (COVID-19) variants contribute to the plans of the next steps on COVID-19 vaccine production, such as Pfizer and Biotech announced on February 25, 2021 that they had started evaluating the safety and immunogenicity of a third dose of their vaccine to observe whether it would boost immunity to SARS-CoV-2 (C)OVID-19) variants, particularly B.1.351; Modern announced on February 24, 2021 that it had shipped a booster vaccine candidate based on B.1.351 to NIAID for a phase 1 trial; and Novavax, whose first-generation vaccine has not been authorized yet in the United States, announced on January 28, 2021 that it was working on developing a booster, a combination bivalent vaccine, or both to protect against SARS-CoV-2 (COVID-19) variants. From experience with avian coronavirus, vaccines against one variant will protect against similar variant, but not always against highly divergent variants. It is hard to predict log term of risk of immune escape. In long term, multivalent vaccines that include the viral nucleoprotein might be more robust. As SARS-CoV-2 (COVID-19) variants are too divergent, similar to flu vaccines, COVID-19 vaccines will be changed. In conclusion, rapid identification and characterization of variants of concern by the national and global surveillance will provide much more proactive. More challenging will be deciding when and how to deploy COVID-19 vaccines 2.0. Modifying COVID-19 vaccines would probably be the most straightforward step in Involving SARS-CoV-2(COVID-19) variants.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Immunology and Microbiology.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Immunology and Microbiology
  • SubjectImmunology & Microbiology
  • SubjectMicrobiology
  • BylineArticles whose byline prints “Attapon Cheepsattayakorn”